Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $19.5 million.

  • OptimizeRx's Cash & Equivalents rose 2104.06% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 2104.06%. This contributed to the annual value of $13.4 million for FY2024, which is 340.75% down from last year.
  • Latest data reveals that OptimizeRx reported Cash & Equivalents of $19.5 million as of Q3 2025, which was up 2104.06% from $16.6 million recorded in Q2 2025.
  • OptimizeRx's 5-year Cash & Equivalents high stood at $89.0 million for Q1 2022, and its period low was $9.8 million during Q2 2023.
  • Its 5-year average for Cash & Equivalents is $38.6 million, with a median of $16.6 million in 2025.
  • Per our database at Business Quant, OptimizeRx's Cash & Equivalents soared by 70520.66% in 2021 and then crashed by 8877.71% in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Cash & Equivalents stood at $84.7 million in 2021, then tumbled by 78.5% to $18.2 million in 2022, then dropped by 23.93% to $13.9 million in 2023, then dropped by 3.41% to $13.4 million in 2024, then skyrocketed by 45.88% to $19.5 million in 2025.
  • Its Cash & Equivalents was $19.5 million in Q3 2025, compared to $16.6 million in Q2 2025 and $16.6 million in Q1 2025.